HOME >> MEDICINE >> NEWS
San Francisco VA researcher receives top Veterans Affairs award

Michael Weiner, MD, a pioneering brain imaging researcher at the San Francisco VA Medical Center (SFVAMC), is a recipient of the 2006 William S. Middleton Award from the Department of Veterans Affairs.

The award the VA's highest scientific honor is given in recognition of outstanding achievement in biomedical research. It was named after the physician who served as the VA's Chief Medical Officer from 1955 to 1963.

Weiner is director of the Center for the Imaging of Neurodegenerative Diseases (CIND) at SFVAMC and a professor of radiology, medicine, psychiatry, and neurology at the University of California, San Francisco (UCSF).

He will receive the award officially on May 15, 2007 in a ceremony in Washington, DC.

As a 2006 recipient, Weiner will receive $50,000 per year for three years in research support, a cash award of $5,000, an announcement of the award in a prestigious scientific journal, and an inscribed plaque commemorating his scientific achievements. SFVAMC will also receive a plaque honoring Weiner's achievements.

Weiner is to be recognized for his "exemplary service to the VA and to the biomedical profession" as well as his contributions to the field of clinical magnetic resonance imaging.

Weiner, a nephrologist by training, joined SFVAMC in 1980 as chief of hemodialysis. In the same year, he first worked with nuclear magnetic resonance (NMR) technology to obtain images of a kidney in a living rat one of the earliest biological applications of NMR. He went on to establish the magnetic resonance imaging program at SFVAMC, and has had a hand in the development of clinical magnetic resonance brain imaging techniques used around the world.

Currently, Weiner is the primary principal investigator of the Alzheimer's Disease Neuroimaging Initiative, a nationwide, multicenter clinical trial designed to establish a brain biomarker for Alzheimer's disease. He is also the principal investigator
'"/>

Contact: Steve Tokar
steve.tokar@ncire.org
415-221-4810, ext. 5202
University of California - San Francisco
15-May-2007


Page: 1 2

Related medicine news :

1. San Franciscos homeless population is getting older
2. San Francisco VA Medical Center invites public to celebrate VA Research Week
3. UC San Franciscos Harrington wins GSAs 2005 Doris Schwartz Gerontological Nursing Award
4. Stanford researchers find culprit in aging muscles that heal poorly
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Penn researchers discover novel pathway for increasing good cholesterol
7. Theory of facial aging gets a facelift from UT Southwestern researchers
8. UIC researchers to develop new drugs to fight bioterrorism
9. Fat is the new normal, FSU researcher says
10. UQ researchers discover some of the oldest forms of life
11. U of M researchers discover new method to combat HIV

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: San Francisco researcher receives top Veterans Affairs award

(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/20/2014)... Orlando, Florida (PRWEB) October 20, 2014 ... fired-up former Gov. Charlie Crist made a brief fundraising ...  in Orlando on Thursday. , Fresh from a debate ... refused to take the stage for the first seven ... podium, the former governor described the incident in one ...
(Date:10/20/2014)... 2014 Women’s health specialist, Dr. Amber ... Gynecology of Columbus, Inc., A Division of MaternOhio Clinical ... more than 100,000 patients annually. Dr. Murphy will provide ... stages of a women’s life. She is accepting new ... Westerville and Dublin. , Dr. Murphy offers a wide ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... Colo. , Oct. 20, 2014  Luoxis ... (NYSE MKT: AMPE), today announced that its academic ... clinical and research potential for its novel RedoxSYS ... potential (ORP) in the body in response to ... value of ORP as a clinical marker will ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: